Table 1.
Cytotoxicity (IC50) of the target hybrids 4a–e, 6a–d, and 8a–d towards HCT-116, HepG-2, MCF-7, and WI-38 cell lines.
|
|||||
|---|---|---|---|---|---|
| Comp. | R | IC50 (µM)a |
|||
| HCT-116 | HepG-2 | MCF-7 | WI-38 | ||
| 4a | 4-F | 5.61 ± 0.3 | 7.92 ± 0.6 | 3.84 ± 0.1 | 45.23 ± 2.6 |
| 4b | 4-OCH3 | 29.92 ± 2.2 | 34.68 ± 2.4 | 22.27 ± 1.7 | 77.57 ± 4.3 |
| 4c | 4-Br | 47.94 ± 2.9 | 65.47 ± 3.6 | 50.05 ± 2.9 | 28.85 ± 2.2 |
| 4d | 4-CH3 | 26.78 ± 2.1 | 21.13 ± 1.8 | 15.48 ± 1.2 | 74.01 ± 4.1 |
| 4e | 3,4,5-(OCH3)3 | 8.24 ± 0.6 | 9.04 ± 0.8 | 6.11 ± 0.4 | 32.81 ± 2.3 |
| 6a | H | 92.45 ± 4.9 | 83.20 ± 4.4 | 72.62 ± 3.9 | 57.84 ± 3.5 |
| 6b | 4-CH3 | 41.68 ± 2.7 | 52.33 ± 3.1 | 39.79 ± 2.3 | 86.20 ± 4.8 |
| 6c | 4-OCH3 | 80.82 ± 4.3 | 76.90 ± 4.0 | 67.38 ± 3.8 | 49.11 ± 2.8 |
| 6d | 4-Cl | 64.41 ± 3.6 | 69.26 ± 3.8 | 58.61 ± 3.2 | 85.66 ± 4.5 |
| 8a | 4-CH3 | 13.89 ± 1.0 | 18.10 ± 1.4 | 10.86 ± 0.8 | 53.10 ± 3.1 |
| 8b | 4-Cl | 54.06 ± 3.2 | 36.98 ± 2.5 | 43.13 ± 2.5 | >100 |
| 8c | 4-Br | 38.29 ± 2.5 | 27.94 ± 2.2 | 31.30 ± 2.1 | >100 |
| 8d | 4-OCH3 | >100 | 87.52 ± 4.7 | 78.22 ± 4.1 | 63.24 ± 3.8 |
| SOR | – | 5.23 ± 0.3 | 4.50 ± 0.2 | 4.17 ± 0.2 | 6.72 ± 0.5 |
aIC50 is defined as the concentration needed to inhibit 50% of cancer cell proliferation. Data are represented as the mean ± SD from the dose-response curves as triplicate . IC50, (µg/mL): 1–10 (very strong), 11–20 (strong), 21–50 (moderate), 51–100 (weak), 100–200 (very weak), above 200 (non-cytotoxic).